Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Respiratory Diseases Dominate Autoimmune/Inflammation Area

By Drug Discovery Trends Editor | May 11, 2011

 In the autoimmune/inflammation therapeutic area, the focus has shifted from rheumatology to respiratory diseases, with COPD and asthma seeing the highest levels of activity, according to a review of clinical trial starts from September 2009 to October 2010 conducted by Citeline analysts.

The review showed inhaled combinations therapies dominated respiratory development, with five pharmaceutical companies (AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer) starting new trials in respiratory disorders.

“In straightforward numeric counts of trial starts, 2010 does not, on the surface, look like an inspirational year for A/I,” stated Laura Runkel, PhD, associate director for Citeline. “However, it has been anything but static with the focus moving from rheumatology to respiratory indications, and particularly high levels of interest in COPD and asthma.”

Active trials in COPD are now outstripping those in asthma. This trend is driven by several major programs for fixed-dose combinations (FDCs) of LABA/LAMA sponsored by Novartis and GSK. “There is a clear battle for market share in chronic indications going on between the leading companies: 71% of the top sponsors’ trial starts were in respiratory diseases and rheumatology,” Runkel continues,  “In contrast, only

Novartis initiated studies in the lower-activity indications, including cystic fibrosis, the gastrointestinal indications, and atopic dermatitis.”  Several drugs with novel mechanisms of action are being developed in the autoimmune/inflammation therapeutic area, including Pfizer’s tofacitinib for rheumatoid arthritis and Vertex’s VX-770 and VX-809 for cystic fibrosis. Other biologics targeting IL-17 and IL-23 are in earlier stages of development.
 
Release Date: May 10, 2011

Source: Citeline 


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE